Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
5(100.0%)
5Total
Phase 4(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06834230Phase 4Recruiting

Effect of Dotinurad in Hyperuricemia With Hypertension

Role: lead

NCT05164653Phase 4Active Not Recruiting

Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

Role: lead

NCT05887817Phase 4Active Not Recruiting

Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)

Role: lead

NCT03506113Phase 4Completed

GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial

Role: collaborator

NCT01760967Phase 4Completed

Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial

Role: collaborator

All 5 trials loaded